You are here

  • Home
  • Archive
  • Volume 10, Issue 10
  • Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)

 

Online download statistics by month:

Online download statistics by month: October 2022 to March 2024

AbstractFullPdf
Oct 2022668677185
Nov 2022349351173
Dec 202222622640
Jan 202317417463
Feb 202313614232
Mar 202314514739
Apr 202313113250
May 202317217346
Jun 2023808129
Jul 2023757655
Aug 2023919144
Sep 2023777745
Oct 2023686842
Nov 202311711749
Dec 2023898947
Jan 2024464731
Feb 2024545428
Mar 2024626471
Total276027861069